Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Appointed director
|
|
Eidos Therapeutics, Inc. (EIDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/05/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 01/28/2021 |
4
| Fox Jonathan C (See Remarks) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Gifted 500 shares
@ $0
Unknown transaction of 380,467 shares
@ $0
Disposed/sold 70,000 options to buy
@ $13.2, valued at
$924k
|
|
| 01/28/2021 |
4
| Rohlen Douglas (Director) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Disposed/sold 21,447 options to buy
@ $41.42, valued at
$888.3k
Disposed/sold 4,526 restricted stock units
@ $0 |
|
| 01/28/2021 |
4
| Valle Franco (Senior Vice President, Finance) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Disposed/sold 24,350 options to buy
@ $7.24, valued at
$176.3k
|
|
| 01/28/2021 |
4
| Turtle Cameron (Chief Business Officer) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Unknown transaction of 50,699 shares
@ $0
Disposed/sold 9,469 options to buy
@ $17, valued at
$161k
Disposed/sold 53,157 options to buy
@ $13.2, valued at
$701.7k
|
|
| 01/28/2021 |
4
| Satvat Ali J. (Director) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Disposed/sold 21,528 options to buy
@ $48.51, valued at
$1M
Disposed/sold 21,528 options to buy
@ $30.87, valued at
$664.6k
Disposed/sold 43,056 options to buy
@ $20.34, valued at
$875.8k
|
|
| 01/28/2021 |
4
| Lis William (Director) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Disposed/sold 21,528 options to buy
@ $48.51, valued at
$1M
Disposed/sold 21,528 options to buy
@ $30.87, valued at
$664.6k
Disposed/sold 43,056 options to buy
@ $13.67, valued at
$588.6k
|
|
| 01/28/2021 |
4
| Hooper Suzanne Sawochka (Director) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Disposed/sold 21,447 options to buy
@ $41.42, valued at
$888.3k
Disposed/sold 4,526 restricted stock units
@ $0 |
|
| 01/28/2021 |
4
| Sinha Uma (Chief Scientific Officer) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Gifted 3,000 shares
@ $0
Unknown transaction of 303,525 shares
@ $0
Disposed/sold 60,000 options to buy
@ $13.2, valued at
$792k
|
|
| 01/28/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/26/2021 |
SC 13D/A
| Eidos Therapeutics, Inc. reports a 0% stake in BridgeBio Pharma, Inc. |
| 01/26/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/26/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/26/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/26/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/26/2021 |
4
| BridgeBio Pharma, Inc. (10% Owner) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Bought 14,428,836 shares
@ $0 |
|
| 01/26/2021 |
SC 13D/A
| BridgeBio Pharma, Inc. reports a 100% stake in Eidos Therapeutics, Inc. |
| 01/26/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/26/2021 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Certificate of Incorporation of Eidos Therapeutics, Inc",
"Amended and Restated Bylaws of Eidos Therapeutics, Inc",
"First Loan Modification Agreement, to the Loan and Security Agreement, by and between Eidos Therapeutics, Inc., as borrower, Silicon Valley Bank, as administrative agent, collateral agent, and lender and Hercules Capital, Inc., as lender" |
|
| 01/26/2021 |
GN
| BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. |
| 01/20/2021 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 01/19/2021 |
GN
| Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. |
| 01/15/2021 |
4
| Sinha Uma (Chief Scientific Officer) has filed a Form 4 on Eidos Therapeutics, Inc.|
Txns:
| Sold 696 shares
@ $121.1094, valued at
$84.3k
Sold 572 shares
@ $122.2667, valued at
$69.9k
Sold 1,498 shares
@ $123.4787, valued at
$185k
Sold 4,934 shares
@ $124.7187, valued at
$615.4k
Sold 2,000 shares
@ $125.35, valued at
$250.7k
Sold 300 shares
@ $126.39, valued at
$37.9k
|
|
| 01/13/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/13/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/13/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/12/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/12/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/12/2021 |
8-K
| Quarterly results |
| 01/07/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/04/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/04/2021 |
GN
| EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm |
| 01/04/2021 |
GN
| Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger |
| 12/30/2020 |
GN
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – CKH, WDR, NAV, EIDX |
|
|
|